I am buying now. The reason for thos is there will be a bump up in price and much more attention when both Phase 3 trials are underway. I also like there is no competition, as this medication is a value-add to tratiotional, increasing both of the drugs used to treat the condition, giving an extra 10% effectiveness. Who would not want an extra effect when this is proposed to a patient. The take up will be by all who are insured or can otherwise pay for this value-add treatment
Opthea shares target raised on trial progress, page-7
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $382.0M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.5¢ | 35.0¢ | $934.4K | 2.624M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 230715 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 17816 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |